Vatalanib
Vatalanib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against vascular endothelial growth factor receptor 2. In addition, it is known to target vascular endothelial growth factor receptor 3, platelet-derived growth factor receptor beta, and vascular endothelial growth factor receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
39 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 2 | 1 | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | — | — | 2 | — | — | 2 |
| Colonic neoplasms | D003110 | — | C18 | — | — | 2 | — | — | 2 |
| Rectal neoplasms | D012004 | — | — | — | — | 2 | — | — | 2 |
| Osteosarcoma | D012516 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 8 | 2 | — | — | — | 9 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 2 | 2 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | — | 3 |
| Central nervous system neoplasms | D016543 | — | — | 2 | 2 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
| Islet cell carcinoma | D018273 | — | C25.4 | 1 | 1 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 2 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | — | 2 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | — | 2 | — | — | — | 2 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
| Insulinoma | D007340 | — | — | 1 | — | — | — | — | 1 |
| Pheochromocytoma | D010673 | — | — | 1 | — | — | — | — | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | 1 | — | — | — | — | 1 |
| Medullary carcinoma | D018276 | — | — | 1 | — | — | — | — | 1 |
| Gastrinoma | D015408 | — | — | 1 | — | — | — | — | 1 |
| Glucagonoma | D005935 | — | — | 1 | — | — | — | — | 1 |
| Somatostatinoma | D013005 | — | — | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vatalanib |
| INN | vatalanib |
| Description | Vatalanib is a member of the class of phthalazines that is phthalazine in which the hydrogens at positions 1 and 4have been replaced by a p-chlorophenylamino group and a pyridin-4-ylmethyl group, respectively. It is a multi-targeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, an angiogenesis inhibitor and a vascular endothelial growth factor receptor antagonist. It is a member of phthalazines, a member of pyridines, a member of monochlorobenzenes and a secondary amino compound. |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 212141-54-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL101253 |
| ChEBI ID | 90620 |
| PubChem CID | 151194 |
| DrugBank | DB04879 |
| UNII ID | 5DX9U76296 (ChemIDplus, GSRS) |
Target
Agency Approved
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
FLT4
FLT4
PDGFRB
PDGFRB
FLT1
FLT1
Organism
Homo sapiens
Gene name
FLT4
Gene synonyms
VEGFR3
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 3
Protein synonyms
Feline McDonough Sarcoma (FMS)-like tyrosine kinase 4, FLT-4, fms related tyrosine kinase 4, Fms-like tyrosine kinase 4, primary congenital lymphedema, Tyrosine-protein kinase receptor FLT4, VEGF receptor-3
Uniprot ID
Mouse ortholog
Flt4 (14257)
vascular endothelial growth factor receptor 3 (P35917)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,918 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use